296P - Efficiency of intermittent androgen blockade in patients with advanced prostate cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Prostate Cancer
Presenter Murod Tashmetov
Citation Annals of Oncology (2016) 27 (suppl_9): ix90-ix93. 10.1093/annonc/mdw584
Authors M.N. Tashmetov1, S.K. Yusupov2
  • 1Oncology, Tashkent Medical Academy, 100169 - Tashkent/UZ
  • 2Oncology, City Oncology Centre, 100154 - Tashkent/UZ



One of the methods to prevent the development of hormone-resistant prostate cancer (PC) is intermittent androgen blockade (IAB). The concept of IAB is in a temporary androgen blockade, in which stem tumor cells are partially preserved. When a certain response is achieved, antiandrogen therapy is stopped to allow the growth of new clones of androgen-sensible cancer cells. Then treatment is resumed. The mechanism of this method is based on the activity of the remaining stem tumor cells, which cause the growth of androgen-dependent colony, receptive to re-hormonal treatment.


The study included 235 patients with advanced prostate cancer who were treated at the City Cancer Center, Tashkent city. Patients were divided into 2 groups: group 1 (n = 49) – patients underwent surgical castration; group 2 (n = 186) - patients received combined hormone therapy. All patients from group 2 were treated in the mode of intermittent therapy with - LHRH agonist - goserelin acetate 3.6 mg in the form of a depot injection 1 time per month and the injection form of cyproterone acetate 300 mg 2 times a month in combination with bisphosphonates.


The study included 235 patients with advanced prostate adenocarcinoma. In group 1 (n = 49), where patients received orchiectomy, the average age of patients was 77.08 ± 1.12 years. In 18 patients (36.7 ± 6.88%) the prevalence of tumor process was T2NxMx, 26 patients (53.1 ± 7.12%) - T3NxMx, 5 patients (10.2 ± 4.32) - T3NxMx. 19 patients (38.7 ± 6.96%) were detected to have skeletal bone metastases, retroperitoneal and iliac lymph nodes.


The results of our research confirm the effectiveness of hormone therapy IAB in comparison with the traditional method of surgical castration. Our certain methods of selecting the optimal mode of hormonal therapy, depending on prognostic factors has led to improved health outcomes and quality of life of patients with advanced prostate cancer. Herewith, determination of the period of the second cycle start of hormone therapy is decided individually for each patient based on the PSA level before treatment and on the extent of tumor spread, dynamics of clinical symptoms, tolerance to androgen blockade.

Clinical trial indentification

Our certain methods of selecting the
optimal mode of hormonal therapy.

Legal entity responsible for the study

Yusupov Sherali Khasanovich


Tashkent city oncology dispanser


All authors have declared no conflicts of interest.